Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Chinese subjects with active non-infectious uveitis
NCT05414201Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in non-infectious intermediate uveitis, Posterior uveitis (non-infectious), non-infectious panuveitis (NIU), sponsored by AbbVie Inc.. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on NCT05414201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414201.